Catumaxomab selectively lyses tumor cells by acting as a bridge for CD3-expressing T-cells, EpCAM-expressing tumor cells, and Fc receptor-expressing accessory cells, such as dendritic cells, macrophages, and NK cells19. This evidence concerns the gene EPCAM and neoplasm.